Edward Tenthoff
Stock Analyst at Piper Sandler
(3.23)
# 1,134
Out of 4,479 analysts
135
Total ratings
41.29%
Success rate
2.55%
Average return
Main Sectors:
Top Industries:
45 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics | Reiterates: Overweight | $16 | $3.59 | +345.68% | 3 | Jun 28, 2024 | |
| MRNA Moderna | Reiterates: Overweight | $214 | $117.07 | +82.80% | 8 | Jun 27, 2024 | |
| TPST Tempest Therapeutics | Reiterates: Overweight | $8 | $2.12 | +277.36% | 3 | Jun 21, 2024 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $53.12 | +97.68% | 4 | Jun 17, 2024 | |
| LEGN Legend Biotech | Reiterates: Overweight | $90 | $44.74 | +101.16% | 3 | Jun 17, 2024 | |
| IPSC Century Therapeutics | Maintains: Overweight | $9 → $12 | $2.21 | +442.99% | 6 | Jun 17, 2024 | |
| FATE Fate Therapeutics | Upgrades: Overweight | $4 → $6 | $3.22 | +86.34% | 5 | Jun 17, 2024 | |
| SYRS Syros Pharmaceuticals | Reiterates: Overweight | $13 | $5.00 | +160.00% | 4 | Apr 3, 2024 | |
| CUE Cue Biopharma | Reiterates: Overweight | $8 | $1.08 | +640.74% | 3 | Apr 3, 2024 | |
| APTO Aptose Biosciences | Maintains: Overweight | $5 | $0.74 | +572.95% | 4 | Apr 3, 2024 | |
| STRO Sutro Biopharma | Reiterates: Overweight | $12 → $11 | $2.96 | +271.62% | 5 | Apr 3, 2024 | |
| OMGA Omega Therapeutics | Reiterates: Overweight | $10 → $9 | $2.07 | +334.78% | 4 | Apr 3, 2024 | |
| OPK OPKO Health | Reiterates: Overweight | $5 | $1.21 | +313.22% | 3 | Apr 1, 2024 | |
| SKYE Skye Bioscience | Reiterates: Overweight | $12 → $20 | $7.56 | +164.55% | 2 | Mar 14, 2024 | |
| ASLN ASLAN Pharmaceuticals | Reiterates: Overweight | $15 → $10 | $0.28 | +3,458.72% | 5 | Mar 13, 2024 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $27 → $29 | $34.65 | -16.31% | 2 | Mar 6, 2024 | |
| MIST Milestone Pharmaceuticals | Maintains: Overweight | $6 → $5 | $1.35 | +270.37% | 3 | Mar 5, 2024 | |
| XNCR Xencor | Downgrades: Neutral | $37 → $24 | $18.26 | +31.43% | 2 | Feb 28, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $13 → $15 | $6.10 | +145.90% | 3 | Feb 28, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $39 → $56 | $30.22 | +85.31% | 4 | Feb 27, 2024 | |
| KRON Kronos Bio | Maintains: Overweight | $7 → $6 | $1.17 | +412.82% | 4 | Dec 19, 2023 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $210 → $217 | $247.61 | -12.36% | 4 | Dec 14, 2023 | |
| PSTX Poseida Therapeutics | Maintains: Overweight | $8 → $10 | $3.02 | +231.13% | 3 | Dec 11, 2023 | |
| ARVN Arvinas | Maintains: Overweight | $70 → $55 | $24.85 | +121.33% | 5 | Oct 23, 2023 | |
| GRTS Gritstone bio | Maintains: Overweight | $6 → $7 | $0.57 | +1,121.64% | 2 | Sep 28, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $28 → $31 | $2.79 | +1,011.11% | 5 | Aug 14, 2023 | |
| GRTX Galera Therapeutics | Downgrades: Neutral | $6 → $0.5 | $0.14 | +270.37% | 2 | Aug 10, 2023 | |
| MESO Mesoblast | Downgrades: Neutral | $28 → $8 | $6.45 | +24.03% | 2 | Aug 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $52 → $59 | $25.22 | +133.94% | 6 | Jun 2, 2023 | |
| XFOR X4 Pharmaceuticals | Initiates: Overweight | $3 | $0.54 | +451.17% | 1 | Dec 12, 2022 | |
| NXTC NextCure | Maintains: Overweight | $13 → $6 | $1.50 | +300.00% | 2 | Nov 4, 2022 | |
| MCRB Seres Therapeutics | Maintains: Overweight | $7 → $9 | $0.70 | +1,183.88% | 3 | Sep 7, 2022 | |
| PRTC PureTech Health | Maintains: Overweight | $37 → $44 | $24.20 | +81.82% | 1 | Aug 25, 2022 | |
| ELOX Eloxx Pharmaceuticals | Maintains: Overweight | $160 → $60 | $0.73 | +8,119.18% | 1 | May 23, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Overweight | $76 → $37 | $19.81 | +86.77% | 1 | May 23, 2022 | |
| APVO Aptevo Therapeutics | Maintains: Overweight | $3,036 → $880 | $0.30 | +295,202.01% | 3 | May 13, 2022 | |
| ARGX argenx SE | Upgrades: Overweight | n/a | $435.49 | - | 3 | Nov 29, 2021 | |
| SYBX Synlogic | Maintains: Overweight | n/a | $1.43 | - | 1 | Sep 20, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | n/a | $473.78 | - | 4 | Jul 30, 2021 | |
| EXEL Exelixis | Maintains: Overweight | n/a | $22.15 | - | 1 | Feb 16, 2021 | |
| MRKR Marker Therapeutics | Downgrades: Neutral | n/a | $5.24 | - | 1 | May 12, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Overweight | n/a | $0.16 | - | 1 | Jan 27, 2020 | |
| IGMS IGM Biosciences | Maintains: Overweight | n/a | $6.40 | - | 1 | Jan 6, 2020 | |
| ASNS Actelis Networks | Initiates: Overweight | n/a | $1.74 | - | 1 | Dec 11, 2017 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | n/a | $1,044.66 | - | 1 | Feb 13, 2017 |
Monte Rosa Therapeutics
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $3.59
Upside: +345.68%
Moderna
Jun 27, 2024
Reiterates: Overweight
Price Target: $214
Current: $117.07
Upside: +82.80%
Tempest Therapeutics
Jun 21, 2024
Reiterates: Overweight
Price Target: $8
Current: $2.12
Upside: +277.36%
CRISPR Therapeutics AG
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $53.12
Upside: +97.68%
Legend Biotech
Jun 17, 2024
Reiterates: Overweight
Price Target: $90
Current: $44.74
Upside: +101.16%
Century Therapeutics
Jun 17, 2024
Maintains: Overweight
Price Target: $9 → $12
Current: $2.21
Upside: +442.99%
Fate Therapeutics
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $3.22
Upside: +86.34%
Syros Pharmaceuticals
Apr 3, 2024
Reiterates: Overweight
Price Target: $13
Current: $5.00
Upside: +160.00%
Cue Biopharma
Apr 3, 2024
Reiterates: Overweight
Price Target: $8
Current: $1.08
Upside: +640.74%
Aptose Biosciences
Apr 3, 2024
Maintains: Overweight
Price Target: $5
Current: $0.74
Upside: +572.95%
Sutro Biopharma
Apr 3, 2024
Reiterates: Overweight
Price Target: $12 → $11
Current: $2.96
Upside: +271.62%
Omega Therapeutics
Apr 3, 2024
Reiterates: Overweight
Price Target: $10 → $9
Current: $2.07
Upside: +334.78%
OPKO Health
Apr 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.21
Upside: +313.22%
Skye Bioscience
Mar 14, 2024
Reiterates: Overweight
Price Target: $12 → $20
Current: $7.56
Upside: +164.55%
ASLAN Pharmaceuticals
Mar 13, 2024
Reiterates: Overweight
Price Target: $15 → $10
Current: $0.28
Upside: +3,458.72%
Dyne Therapeutics
Mar 6, 2024
Maintains: Overweight
Price Target: $27 → $29
Current: $34.65
Upside: -16.31%
Milestone Pharmaceuticals
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.35
Upside: +270.37%
Xencor
Feb 28, 2024
Downgrades: Neutral
Price Target: $37 → $24
Current: $18.26
Upside: +31.43%
Fulcrum Therapeutics
Feb 28, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $6.10
Upside: +145.90%
Kymera Therapeutics
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $30.22
Upside: +85.31%
Kronos Bio
Dec 19, 2023
Maintains: Overweight
Price Target: $7 → $6
Current: $1.17
Upside: +412.82%
Alnylam Pharmaceuticals
Dec 14, 2023
Maintains: Overweight
Price Target: $210 → $217
Current: $247.61
Upside: -12.36%
Poseida Therapeutics
Dec 11, 2023
Maintains: Overweight
Price Target: $8 → $10
Current: $3.02
Upside: +231.13%
Arvinas
Oct 23, 2023
Maintains: Overweight
Price Target: $70 → $55
Current: $24.85
Upside: +121.33%
Gritstone bio
Sep 28, 2023
Maintains: Overweight
Price Target: $6 → $7
Current: $0.57
Upside: +1,121.64%
RAPT Therapeutics
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $2.79
Upside: +1,011.11%
Galera Therapeutics
Aug 10, 2023
Downgrades: Neutral
Price Target: $6 → $0.5
Current: $0.14
Upside: +270.37%
Mesoblast
Aug 4, 2023
Downgrades: Neutral
Price Target: $28 → $8
Current: $6.45
Upside: +24.03%
Arrowhead Pharmaceuticals
Jun 2, 2023
Maintains: Overweight
Price Target: $52 → $59
Current: $25.22
Upside: +133.94%
X4 Pharmaceuticals
Dec 12, 2022
Initiates: Overweight
Price Target: $3
Current: $0.54
Upside: +451.17%
NextCure
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $1.50
Upside: +300.00%
Seres Therapeutics
Sep 7, 2022
Maintains: Overweight
Price Target: $7 → $9
Current: $0.70
Upside: +1,183.88%
PureTech Health
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $24.20
Upside: +81.82%
Eloxx Pharmaceuticals
May 23, 2022
Maintains: Overweight
Price Target: $160 → $60
Current: $0.73
Upside: +8,119.18%
Bicycle Therapeutics
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $19.81
Upside: +86.77%
Aptevo Therapeutics
May 13, 2022
Maintains: Overweight
Price Target: $3,036 → $880
Current: $0.30
Upside: +295,202.01%
argenx SE
Nov 29, 2021
Upgrades: Overweight
Price Target: n/a
Current: $435.49
Upside: -
Synlogic
Sep 20, 2021
Maintains: Overweight
Price Target: n/a
Current: $1.43
Upside: -
Vertex Pharmaceuticals
Jul 30, 2021
Maintains: Overweight
Price Target: n/a
Current: $473.78
Upside: -
Exelixis
Feb 16, 2021
Maintains: Overweight
Price Target: n/a
Current: $22.15
Upside: -
Marker Therapeutics
May 12, 2020
Downgrades: Neutral
Price Target: n/a
Current: $5.24
Upside: -
Matinas BioPharma Holdings
Jan 27, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.16
Upside: -
IGM Biosciences
Jan 6, 2020
Maintains: Overweight
Price Target: n/a
Current: $6.40
Upside: -
Actelis Networks
Dec 11, 2017
Initiates: Overweight
Price Target: n/a
Current: $1.74
Upside: -
Regeneron Pharmaceuticals
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $1,044.66
Upside: -